Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI could help GPs catch hidden liver disease before It's too late

NCT ID NCT07305324

Diagnosis Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether an AI tool called FibroX can help primary care providers better diagnose advanced liver fibrosis in people with MASLD, a common liver condition. Forty providers will review simulated patient cases, using either standard methods or FibroX, which gives a risk score and explanation. The goal is to see if the AI improves diagnostic accuracy, trust, and ease of use, potentially leading to earlier detection and better care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FibroX (AI software tool)
What this could lead to
If successful, this AI tool could help primary care doctors catch liver scarring earlier and more accurately, potentially reducing unnecessary referrals and missed diagnoses.
What could go wrong
This is a small pilot study with only 40 providers using simulated cases, not real patients. The AI may not work as well in real-world clinics or with diverse populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Licensed primary care providers (MD, DO, NP, or PA) * Currently practicing in adult primary care (≥0.5 Full-Time Equivalent) * Affiliated with one of the participating clinics (academic, community, or Federally Qualified Health Center) * Willing and able to participate in simulated electronic health record (EHR)-based case reviews * Able to provide informed consent Exclusion Criteria: * Providers not actively practicing in adult primary care * Providers with less than 0.5 FTE in clinical practice * Prior involvement in the development or validation of the FibroX tool * Inability to complete both simulation periods due to scheduling or other constraints

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fibrosis of liver are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver fibrotic liver disease metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fibrosis of liver MASLD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.